Projektbeschreibung
Transmembrandomänen als neuartige therapeutische Wirkstoffziele
Membranproteine sind wichtige therapeutische Zielstrukturen bei der Behandlung einer ganzen Reihe von Krankheiten. Abhängig von der Art der Ligandenbindungsstellen auf diesen Proteinen ist die Wirkstoffspezifität jedoch begrenzt, sodass oft Nebenwirkungen die Folge sind. Neuen Erkenntnissen zur Wechselwirkung zwischen Transmembrandomänen (TMD) und Plasmamembranlipiden folgend befasste sich das EU-finanzierte Projekt Lipopeutics nun mit allosterischen Wirkstoffen, um diese Proteinbestandteile zu verändern. An molekulardynamischen Simulationsmodellen sollen spezifische Lipidbindungsstellen in Transmembrandomänen identifiziert und Substanzen entwickelt werden, die in der hydrophoben TMD-Tasche binden und so die Proteinfunktion stabilisieren können.
Ziel
Membrane proteins constitute a third of the human proteome and their relevance to disease has led these proteins to make up more than half of all current drug targets. However, despite this push to identify agents for membrane proteins, the number of established disease-associated targets are limited. The 'open' and solvent-accessible nature of most membrane protein orthosteric sites often results in limited specificity of potential drugs.
The Trans-Membrane domains (TMD) while displaying greater variability among membrane proteins were however long considered lacking in specific interactions. But significant developments in experimental techniques are now identifying this domain to interact and be actively regulated by the diverse lipid components of the membrane. This Lipopeutics project attempts to determine if the analysis of the protein's Lipid interactions can be a pathway to the development of allosteric drugs targeted at these bilayer-exposed pockets.
Unfolding in three major steps, the project first aims to identify specific lipid binding sites with the TMD through the use of long-timescale coarse-grain Molecular Dynamics simulations. Subsequently, the role of this lipid binding event in the protein's functional modulation is validated through atomistic simulations using the Markov State Modelling approach. Finally, cheminformatic screening is used to design lipid-mimicking compounds that are capable of binding within the hydrophobic pocket and stabilizing specific protein functional states.
Wissenschaftliches Gebiet
Schlüsselbegriffe
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Koordinator
100 44 Stockholm
Schweden